Skip to content
Articaine
Orabloc, Septocaine (articaine) is a small molecule pharmaceutical. Articaine was first approved as Septocaine on 2000-04-03. It is used to treat pain in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
signs and symptoms pathological conditionsD013568
psychological phenomenaD011579
musculoskeletal and neural physiological phenomenaD055687
Trade Name
FDA
EMA
Combinations
Orabloc, Septocaine (discontinued: Ultacan)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Articaine hydrochloride
+
Epinephrine bitartrate
Tradename
Company
Number
Date
Products
SEPTOCAINEDeprocoN-020971 RX2000-04-03
2 products, RLD, RS
ORABLOCPierrelN-022466 RX2010-02-26
2 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
articaine hydrochloride and epinephrineNew Drug Application2022-12-12
orablocNew Drug Application2018-11-22
septocaine and epinephrineNew Drug Application2020-03-18
ultacan ultacan forteANDA2017-07-20
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
painEFO_0003843D010146R52
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
N: Nervous system drugs
N01: Anesthetics
N01B: Local anesthetics
N01BB: Amide local anesthetics
N01BB08: Articaine
N01BB58: Articaine, combinations
HCPCS
No data
Clinical
Clinical Trials
164 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
MalariaD008288EFO_0001068B5498234521101
Falciparum malariaD016778EFO_0007444B502111621649
Hiv infectionsD015658EFO_0000764B202158
Vivax malariaD016780EFO_0007445B511247
HivD006678O98.7213
AnemiaD000740EFO_0004272D64.922
Drug interactionsD00434711
TuberculosisD014376EFO_0000774A15-A1911
SchistosomiasisD012552EFO_1001475B6511
HelminthiasisD006373EFO_1001342B65-B8311
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Covid-19D000086382U07.111
FeverD005334HP_0001945R50.911
Asymptomatic diseasesD058070111
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients313
PharmacokineticsD010599212
Schistosomiasis haematobiaD012553EFO_0007530B65.011
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Parasitic diseasesD010272EFO_0001067B8811
ParasitemiaD01851211
Protozoan infectionsD011528B50-B6411
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PneumoniaD011014EFO_0003106J1822
Drug resistanceD004351Z16.3011
MalnutritionD044342EFO_0008572E40-E4611
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameARTICAINE
INNarticaine
Description
4-methyl-3-[[1-oxo-2-(propylamino)propyl]amino]-2-thiophenecarboxylic acid methyl ester is a thiophenecarboxylic acid.
Classification
Small molecule
Drug classlocal anesthetics
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CCCNC(C)C(=O)Nc1c(C)csc1C(=O)OC
Identifiers
PDB
CAS-ID23964-58-1
RxCUI592464
ChEMBL IDCHEMBL1093
ChEBI ID
PubChem CID32170
DrugBankDB09009
UNII IDD3SQ406G9X (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 1,685 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
318 adverse events reported
View more details